Abstracts Archive - Page 1226 of 2607 - ACR Meeting Abstracts

Abstract Number: 595 • 2018 ACR/ARHP Annual Meeting
Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab
Sheila Melchor¹, Esther Rodriguez-Almaraz², Jose L. Pablos³ and Patricia Carreira⁴, ¹Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain., Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Servicio de Reumatología, Rheumatology Department, Hospital 12 de Octubre, Spain, Madrid, Spain, ⁴Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: Rituximab (RTX) is directed against CD20 antigens in B lymphocytes (BL), producing selective depletion of BL, not affecting mature plasmatic cells, without immediate effect…
Abstract Number: 596 • 2018 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada², Toshikatsu Kanazawa² and Kazuhiko Hatta³, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology, hiroshima clinic, hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, we experienced that rapid radiographic progression (RRP) existed despite initial tofacitinib and methotrexate…
Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Nancy A. Shadick¹, Michael E Weinblatt¹, Christine K Iannaccone², Michelle Frits³, Tigwa Davis⁴, Christopher Young⁴, David H. Collier⁵, Mahdi Gharaibeh⁵ and Bradley S. Stolshek⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Health Analytics, LLC, Columbia, MD, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 600 • 2018 ACR/ARHP Annual Meeting
Early Versus Delayed Treatment in Patients with Rheumatoid Arthritis (RA) in Routine Care at a Single US Academic Center: Better Response According to MDHAQ (MultiDimensional Health Assessment questionnaire) for Patients Starting Treatment in the Initial 6 Months
Jacquelin R. Chua, Mariam Riad, Sobia Hassan, Najia Shakoor, Joel A. Block and Isabel Castrejón, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Delay in initiation of disease-modifying anti-rheumatic drug (DMARD) therapy may be a major contributing factor toward poor outcomes in patients with rheumatoid arthritis (RA).…
Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
René-Marc Flipo¹, Alain Saraux², Christophe Hudry³, Cécile Gaujoux-Viala⁴, Eric Senbel⁵, Sonia Tropé⁶, Elena Zinovieva⁷, Agnès Courbeyrette⁸ and Hélène Herman-Demars⁷, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology, CHU Brest, Brest, France, ³AP-HP Hôpital Cochin, Paris, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology office, Marseille, France, ⁶149 avenue du Maine, ANDAR, Paris, France, ⁷Medical Department Nordic Pharma, Paris, France, ⁸Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…
Abstract Number: 602 • 2018 ACR/ARHP Annual Meeting
Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring
Silje Watterdal Syversen¹, Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Johanna Gehin³, Cato Mork⁴, Tore Kvien⁵, Jorgen Jahnsen⁶, Nils Bolstad³ and Espen A. Haavardsholm⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴None, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
Background/Purpose: The purpose is to develop an individualised treatment strategy based on Therapeutic drug monitoring (TDM) in order to optimise efficacy of Infliximab (INX) treatment.…
Abstract Number: 603 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
Gyanendra Pokharel¹, Rob Deardon¹, Sindhu Johnson², George A. Tomlinson³ and Glen Hazlewood⁴, ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…
Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Gyanendra Pokharel¹, Rob Deardon¹, Cheryl Barnabe², Vivian P. Bykerk³, Susan J. Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Janet E. Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Glen Hazlewood¹², ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁶Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Astrid Thiele⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…
Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
Berrin Zengin¹, Nevsun Inanc², Servet Akar³, Gerçek Can¹, Ediz Dalkiliç⁴, Abdurrahman Tufan⁵, Soner Senel⁶, Suleyman Serdar Koca⁷, Handan Yarkan¹, Yavuz Pehlivan⁸, Zeynep Erturk⁹, Berna Goker⁵, Haner Direskeneli², Merih Birlik¹, Nurullah Akkoc¹⁰ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁶Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁷Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁸Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, ⁹Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, ¹⁰Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…
Abstract Number: 607 • 2018 ACR/ARHP Annual Meeting
Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial
Tsutomu Takeuchi¹, Josef S. Smolen², Roy Fleischmann³, Noriko Iikuni⁴, Haiyun Fan⁵, Koshika Soma⁶, Ermeg Akylbekova⁷ and Tomohiro Hirose⁸, ¹Keio University, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT, ⁷IQVIA, Durham, NC, ⁸Pfizer Japan Inc, Tokyo, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055), a 12-month, global, Phase 3b/4 study, demonstrated that in…
Abstract Number: 608 • 2018 ACR/ARHP Annual Meeting
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
Takeshi Suzuki, Takayasu Ando, Shoshi Shinagawa, Machiko Mizushima, Tomohiko Shibata and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Recently, it is recommended that tapering csDMARDs could be considered If a patient is in persistent remission. However, the methods of tapering csDMARDs including…
Abstract Number: 609 • 2018 ACR/ARHP Annual Meeting
Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice
Alper Sari¹, Levent Kilic¹, Berkan Armagan¹, Abdulsamet Erden², Gozde Yardımcı¹, Ali Akdogan², Omer Karadag², Sule Apras Bilgen², Ihsan Ertenli² and Sedat Kiraz², ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey
Background/Purpose: Biologic DMARDs (bDMARDs) have proven efficacy in rheumatoid arthritis (RA) however, some patients inadequately response to multiple bDMARDs. This study aims to determine the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].